Wyeth and Elan have suspended dosing patients in a mid-stage study of the experimental Alzheimer's vaccine ACC-001 after seeing one of the patients in the study develop skin lesions. Studies of ACC-001 that have been mounted outside of the U.S. have also been suspended. Researchers, though, quickly sought to reassure investors that another late-stage program for AAB-001 wasn't affected by the unexplained case of lesions. AAB-001, or bapineuzumab, has demonstrated an improvement in cognitive function in Alzheimer's patients in a small study and is being closely followed by the investment community.
- read the story [1] in the Wall Street Journal
- read the story [2] in TheStreet.com
Related Articles:
Wyeth stumbles badly trying to develop new drugs
Wyeth, Elan advance Phase III Alzheimer's trial [3]
Links:
[1] http://online.wsj.com/article/SB120846940996624349.html?mod=googlenews_wsj
[2] http://www.thestreet.com/s/wyeth-elan-halt-alzheimer-drug-trial/newsanalysis/biotech/10412498.html?puc=googlen&cm_ven=GOOGLEN&cm_cat=FREE&cm_ite=NA
[3] http://www.fiercebiotech.com/story/wyeth-elan-advance-phase-iii-alzheimer-s-trial/2007-05-21